Efficacy and Safety of Once-Weekly Semaglutide Versus Once-Daily Insulin Glargine as Add-on to Metformin (with or Without Sulfonylureas) in Insulin-Naive Patients with Type 2 Diabetes (SUSTAIN 4): A Randomised, Open-Label, Parallel-Group, Multicentre, Multinational, Phase 3a Trial
Sequencing was performed using a HiSeq 2500 (Illumina), with a read length of 300 bp paired-end reads and at least 25,000 tags per sample
Rare allergic reactions, including anaphylaxis, have been reported
Any peptide protocol is supervised by a licensed provider after an in person evaluation
If you are struggling to follow these instructions or have questions, please do not hesitate to contact us and we will do our best to assist you